Inhaled drug therapy for treatment of tuberculosis

Tuberculosis

Volumn 91, Issue 1, 2011, Pages 71-81

  Misra, Amit ^a   Hickey, Anthony J ^b   Rossi, Carlo ^c   Borchard, Gerrit ^d   Terada, Hiroshi ^e   Makino, Kimiko ^e   Fourie, P Bernard ^f   Colombo, Paolo ^g  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b University of North Carolina   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e TOKYO UNIVERSITY OF SCIENCE   (Japan)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^g UNIVERSITY OF PARMA   (Italy)

Author keywords

Capreomycin; Dry powder inhalation; Isoniazid; Microspheres; Nanoparticles; Nebulization; Pulmonary drug delivery; Rifampicin

Indexed keywords

AMIKACIN; CAPREOMYCIN; DRUG VEHICLE; ISONIAZID; MICROPARTICLE; NANOPARTICLE; POLY(LACTIC CO GLYCOLIC ACID); POLYMER; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AEROSOL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; HUMAN; LIPID VESICLE; LUNG ALVEOLUS MACROPHAGE; METERED DOSE INHALER; NEBULIZATION; NONHUMAN; POWDER INHALER; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ADMINISTRATION, INHALATION; AEROSOLS; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; MACROPHAGE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 79551498057     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.08.009     Document Type: Review

References (127)

1. T.A. Berishvili [PAS inhalation therapy of respiratory tuberculosis in the sanatorium LIBANI; preliminary communication.] Probl Tuberk 4 1954 69 70
2. N.M. Kulik [Inhalation of cycloserine in the complex therapy of patients with pulmonary tuberculosis] Probl Tuberk 45 1967 38 40
3. N.M. Kulik [Inhalation therapy of tuberculosis patients with antitubercular agents of the first and second line] Probl Tuberk 1974 34 37
4. N.M. Kulik [Treatment of pulmonary tuberculosis by the inhalation of aerosols of antibacterial preparations and pathogenetic agents] Probl Tuberk 1980 40 42
5. N.S. Pilipchuk, and R.G. Protsiuk [Effect of inhalation of aerosols of antitubercular preparations on pulmonary surfactant] Vrach Delo 1986 21 25
6. R.G. Protsiuk [Effect of the inhalation of tuberculostatic aerosols on the dynamics of bacterial excretion in pulmonary tuberculosis patients] Probl Tuberk 1983 38 42
7. R.G. Protsiuk [Effect of the inhalation of drug aerosols on external respiration in pulmonary tuberculosis patients] Klin Med (Mosk) 63 1985 50 55
8. E.V. Semenova [Basis for the administration of streptomycin and isoniazid in ultrasonic aerosols in the treatment of intrathoracic tuberculosis] Antibiotiki 22 1977 p. 469-471
9. N.R. Mathias, and M.A. Hussain Non-invasive systemic drug delivery: developability considerations for alternate routes of administration J Pharm Sci 99 2010 1 20
10. C. Lombry, D.A. Edwards, V. Preat, and R. Vanbever Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules Am J Physiol Lung Cell Mol Physiol 286 2004 L1002 L1008
11. W. Moller, W. Barth, M. Kohlhaufl, K. Haussinger, W. Stahlhofen, and J. Heyder Human alveolar long-term clearance of ferromagnetic iron oxide microparticles in healthy and diseased subjects Exp Lung Res 27 2001 547 568
12. A.B. Yadav, R. Sharma, P. Muttil, A.K. Singh, R.K. Verma, and M. Mohan Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy Indian J Exp Biol 47 2009 469 474
13. C. Evora, I. Soriano, R.A. Rogers, K.N. Shakesheff, J. Hanes, and R. Langer Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine J Control Release 51 1998 143 152
14. M.A. Myers, D.A. Thomas, L. Straub, D.W. Soucy, R.W. Niven, and M. Kaltenbach Pulmonary effects of chronic exposure to liposome aerosols in mice Exp Lung Res 19 1993 1 19
15. E.G. Shephard, J.R. Joubert, M.C. Finkelstein, and S.H. Kuhn Phagocytosis of liposomes by human alveolar macrophages Life Sci 29 1981 2691 2698
16. P. Forsgren, J. Modig, B. Gerdin, B. Axelsson, and M. Dahlback Intrapulmonary deposition of aerosolized Evans blue dye and liposomes in an experimental porcine model of early ARDS Ups J Med Sci 95 1990 117 136
17. Y. Sibille, and H.Y. Reynolds Macrophages and polymorphonuclear neutrophils in lung defense and injury Am Rev Respir Dis 141 1990 471 501
18. A. Kahnert, P. Seiler, M. Stein, S. Bandermann, K. Hahnke, and H. Mollenkopf Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis Eur J Immunol 36 2006 631 647
19. R. Sharma, P. Muttil, A.B. Yadav, S.K. Rath, V.K. Bajpai, and U. Mani Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra J Antimicrob Chemother 59 2007 499 506
20. H. Terada, K. Makino, and G.-I. Soma Remedy PCT Int Pat Appl 2004 WO/2004/019982
21. C.F. Lange, and W.H. Finlay Liquid atomizing: nebulizing and other methods of producing aerosols J Aerosol Med 19 2006 28 35
22. W. Berger Aerosol devices and asthma therapy Curr Drug Deliv 6 2009 38 49
23. J.B. Fink Metered-dose inhalers, dry powder inhalers, and transitions Respir Care 45 2000 623 635
24. J.L. Rau Practical problems with aerosol therapy in COPD Respir Care 51 2006 158 172
25. S.P. Newman Spacer devices for metered dose inhalers Clin Pharmacokinet 43 2004 349 360
26. S. Onoue, S. Misaka, Y. Kawabata, and S. Yamada New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy Expert Opin Drug Deliv 6 2009 793 811
27. Century T. Personal communication, 2010.
28. M. Bivas-Benita, K.E. van Meijgaarden, K.L. Franken, H.E. Junginger, G. Borchard, and T.H. Ottenhoff Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A0201-restricted T-cell epitopes of Mycobacterium tuberculosis Vaccine 22 2004 1609 1615
29. M. Bivas-Benita, R. Zwier, H.E. Junginger, and G. Borchard Non-invasive pulmonary aerosol delivery in mice by the endotracheal route Eur J Pharm Biopharm 61 2005 214 218
30. J. Kaur, P. Muttil, R.K. Verma, K. Kumar, A.B. Yadav, and R. Sharma A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages Eur J Pharm Sci 34 2008 56 65
31. A.J. Hickey, and D. Ganderton Pharmaceutical process engineerning 2010 Informa Healthcare New York
32. P. O'Hara, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization Pharm Res 17 2000 955 961
33. M.K. Taylor, A.J. Hickey, and M. VanOort Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles Pharm Dev Technol 11 2006 321 336
34. A.J. Hickey, and H.M. Mansour Delivery of drugs by the pulmonary route A.T. Florence, J. Siepman, Modern pharmaceutics: informa healthcare 2009
35. P. Muttil, C. Wang, and A.J. Hickey Inhaled drug delivery for tuberculosis therapy Pharm Res 2009
36. R. Vehring Pharmaceutical particle engineering via spray drying Pharm Res 25 2008 999 1022
37. A. Schoubben, P. Blasi, S. Giovagnoli, M. Ricci, and C. Rossi Simple and scalable method for peptide inhalable powder production Eur J Pharm Sci 39 2010 53 58
38. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J Antimicrob Chemother 52 2003 981 986
39. A. Sharma, S. Sharma, and G.K. Khuller Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis J Antimicrob Chemother 54 2004 761 766
40. A. Zahoor, S. Sharma, and G.K. Khuller Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis Int J Antimicrob Agents 26 2005 298 303
41. J.C. Sung, B.L. Pulliam, and D.A. Edwards Nanoparticles for drug delivery to the lungs Trends Biotechnol 25 2007 563 570
42. N. Tsapis, D. Bennett, B. Jackson, D.A. Weitz, and D.A. Edwards Trojan particles: large porous carriers of nanoparticles for drug delivery Proc Natl Acad Sci U S A 99 2002 12001 12005
43. B.E. Gilbert Liposomal aerosols in the management of pulmonary infections J Aerosol Med 9 1996 111 122
44. T.C. Whitehead, A.M. Lovering, I.M. Cropley, P. Wade, and R.N. Davidson Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis Eur J Clin Microbiol Infect Dis 17 1998 794 797
45. R.M. Fielding, R.O. Lewis, and L. Moon-McDermott Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome) Pharm Res 15 1998 1775 1781
46. S. Giovagnoli, P. Blasi, C. Vescovi, G. Fardella, I. Chiappini, and L. Perioli Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization AAPS PharmSci Tech 4 2005 E69
47. M. Ricci, S. Giovagnoli, P. Blasi, A. Schoubben, L. Perioli, and C. Rossi Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation Int J Pharm 311 2006 172 181
48. R. Pandey, S. Sharma, and G.K. Khuller Nebulization of liposome encapsulated antitubercular drugs in guinea pigs Int J Antimicrob Agents 24 2004 93 94
49. J. Weers, B. Metzheiser, G. Taylor, S. Warren, P. Meers, and W.R. Perkins A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers J Aerosol Med Pulm Drug Deliv 22 2009 131 138
50. S.P. Vyas, M.E. Kannan, S. Jain, V. Mishra, and P. Singh Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages Int J Pharm 269 2004 37 49
51. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications Br J Clin Pharmacol 56 2003 600 612
52. P.P. Le Brun, A.H. de Boer, H.G. Heijerman, and H.W. Frijlink A review of the technical aspects of drug nebulization Pharm World Sci 22 2000 75 81
53. Z. Li, Y. Zhang, W. Wurtz, J.K. Lee, V.S. Malinin, and S. Durwas-Krishnan Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size J Aerosol Med Pulm Drug Deliv 21 2008 245 254
54. A. Jobe, M. Ikegami, and P.W. Nathanielsz The labelling of pulmonary surfactant phosphatidylcholine in 19-31-days-old lambs J Dev Physiol 1 1979 245 259
55. L. Garcia-Contreras, J. Fiegel, M.J. Telko, K. Elbert, A. Hawi, and M. Thomas Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob Agents Chemother 51 2007 2830 2836
56. J. Fiegel, L. Garcia-Contreras, M. Thomas, J. VerBerkmoes, K. Elbert, and A. Hickey Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm Res 25 2008 805 811
57. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, and D.N. McMurray Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model Pharm Res 18 2001 1315 1319
58. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm Res 18 2001 1405 1410
59. L. Garcia-Contreras, V. Sethuraman, M. Kazantseva, V. Godfrey, and A.J. Hickey Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig J Antimicrob Chemother 58 2006 980 986
60. H. Zhou, Y. Zhang, D.L. Biggs, M.C. Manning, T.W. Randolph, and U. Christians Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages J Control Release 107 2005 288 299
61. P. Muttil, J. Kaur, K. Kumar, A.B. Yadav, R. Sharma, and A. Misra Inhalable microparticles containing large payload of anti-tuberculosis drugs Eur J Pharm Sci 32 2007 140 150
62. Giovagnoli S, Sonoara D, Blasi P, Ricci M, Perioli L, Rossi C. Preparation and characterization of respirable biodegradable microspheres for capreomycin pulmonary delivery. In: 12th International Pharmaceutical Technology Symposium, 2004.
63. P. Blasi, A. Schoubben, S. Giovagnoli, C. Rossi, and M. Ricci Fighting tuberculosis: old drugs, new formulations Expert Opin Drug Deliv 6 2009 977 993
64. K. Hirota, T. Hasegawa, T. Nakajima, H. Inagawa, C. Kohchi, and G. Soma Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis J Control Release 142 2010 339 346
65. S.M. Hwang, D.D. Kim, S.J. Chung, and C.K. Shim Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis J Control Release 129 2008 100 106
66. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int J Pharm 392 2010 1 19
67. H.D. Smyth The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers Adv Drug Deliv Rev 55 2003 807 828
68. M.C. Liu, R.J. Riese, K. Van Gundy, P. Norwood, B.E. Sullivan, and P.F. Schwartz Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes Eur Respir J 32 2008 180 188
69. S.E. Fineberg, T. Kawabata, D. Finco-Kent, C. Liu, and A. Krasner Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial J Clin Endocrinol Metab 90 2005 3287 3294
70. G. Chimote, and R. Banerjee Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis J Biomed Mater Res A 89 2009 281 292
71. G. Chimote, and R. Banerjee Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis Respir Physiol Neurobiol 162 2008 73 79
72. G. Chimote, and R. Banerjee In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis J Biomed Mater Res B Appl Biomater 94 2010 1 10
73. K. Hirota, K. Tomoda, H. Inagawa, C. Kohchi, G. Soma, and K. Makino Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria Pharm Res 25 2008 1420 1430
74. D.M. Bowdish, K. Sakamoto, M.J. Kim, M. Kroos, S. Mukhopadhyay, and C.A. Leifer MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis PLoS Pathog 5 2009 e1000474
75. K. Hirota, T. Hasegawa, H. Hinata, F. Ito, H. Inagawa, and C. Kochi Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages J Control Release 119 2007 69 76
76. T. Hasegawa, K. Hirota, K. Tomoda, F. Ito, H. Inagawa, and C. Kochi Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent Colloids Surf B Biointerfaces 60 2007 221 228
77. L. Garcia-Contreras, Y.L. Wong, P. Muttil, D. Padilla, J. Sadoff, and J. Derousse Immunization by a bacterial aerosol Proc Natl Acad Sci U S A 105 2008 4656 4660
78. A.J. Hickey, T.B. Martonen, and Y. Yang Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols Pharm Acta Helv 71 1996 185 190
79. L.V. Sacks, S. Pendle, D. Orlovic, M. Andre, M. Popara, and G. Moore Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis Clin Infect Dis 32 2001 44 49
80. N. Tsapis, D. Bennett, K. O'Driscoll, K. Shea, M.M. Lipp, and K. Fu Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis (Edinb) 83 2003 379 385
81. S. Sturgill-Koszycki, P.H. Schlesinger, P. Chakraborty, P.L. Haddix, H.L. Collins, and A.K. Fok Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase Science 263 1994 678 681
82. G. Ferrari, H. Langen, M. Naito, and J. Pieters A coat protein on phagosomes involved in the intracellular survival of mycobacteria Cell 97 1999 435 447
83. S. Prior, B. Gander, N. Blarer, H.P. Merkle, M.L. Subira, and J.M. Irache In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres Eur J Pharm Sci 15 2002 197 207
84. A.M. Torche, P. Le Corre, E. Albina, A. Jestin, and R. Le Verge PLGA microspheres phagocytosis by pig alveolar macrophages: influence of poly(vinyl alcohol) concentration, nature of loaded-protein and copolymer nature J Drug Target 7 2000 343 354
85. B.G. Jones, P.A. Dickinson, M. Gumbleton, and I.W. Kellaway Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383 J Pharm Pharmacol 54 2002 1065 1072
86. B.G. Jones, P.A. Dickinson, M. Gumbleton, and I.W. Kellaway The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages Int J Pharm 236 2002 65 79
87. R.K. Verma, J. Kaur, K. Kumar, A.B. Yadav, and A. Misra Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice Antimicrob Agents Chemother 52 2008 3195 3201
88. Z. Ahmad, R. Pandey, S. Sharma, and G.K. Khuller Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential Indian J Chest Dis Allied Sci 48 2006 171 176
89. A.B. Yadav, P. Muttil, A.K. Singh, R.K. Verma, M. Mohan, and A.K. Agrawal Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis Tuberculosis (Edinb) 90 2010 188 196
90. A.B. Yadav, and A. Misra Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity Antimicrob Agents Chemother 51 2007 3740 3742
91. N. Brandhonneur, F. Chevanne, V. Vie, B. Frisch, R. Primault, and M.F. Le Potier Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages Eur J Pharm Sci 36 2009 474 485
92. A. Yoshida, M. Matumoto, H. Hshizume, Y. Oba, T. Tomishige, and H. Inagawa Selective delivery of rifampicin incorporated into poly(DL-lactic-co- glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin Microbes Infect 8 2006 2484 2491
93. D.S. Sukhanov, A.K. Ivanov, A.L. Kovalenko, E.G. Dziuba, M.N. Andreeva, and M.G. Romantsov [Pathogenetic therapy of tuberculosis of respiratory organs during sanatorium-and-spa treatment] Vopr Kurortol Fizioter Lech Fiz Kult 2009 34 37
94. T. Rikimaru, and K. Oizumi [Aerosolized therapy with streptomycin and steroids in treatment of bronchial stenosis due to endobronchial tuberculosis] Kekkaku 74 1999 879 883
95. T. Rikimaru [Evaluation of aerosol therapy of streptomycin for tracheobronchial tuberculosis] Kekkaku 69 1994 733 738
96. T. Rikimaru, Y. Tanaka, E. Higuchi, M. Katsuki, Y. Ichikawa, and K. Oizumi [Evaluation of aerosol therapy of streptomycin for tracheobronchial and pulmonary tuberculosis] Kansenshogaku Zasshi 66 1992 206 211
97. R. Condos, W.N. Rom, and N.W. Schluger Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol Lancet 349 1997 1513 1515
98. R. Condos, F.P. Hull, N.W. Schluger, W.N. Rom, and G.C. Smaldone Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis Chest 125 2004 2146 2155
99. W.J. Koh, O.J. Kwon, G.Y. Suh, M.P. Chung, H. Kim, and N.Y. Lee Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis J Korean Med Sci 19 2004 167 171
100. P.R. Grahmann, and R.K. Braun A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study Int J Tuberc Lung Dis 12 2008 636 644
101. S. Giosue, M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, and G. Pedicelli Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis Am J Respir Crit Care Med 158 1998 1156 1162
102. M. Netea, F.L. van de Veerdonk, B.J. Kullberg, J.W. Van der Meer, and L.A. Joosten The role of NLRs and TLRs in the activation of the inflammasome Expert Opin Biol Ther 8 2008 1867 1872
103. I. Brodsky, and D. Monack NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens Semin Immunol 21 2009 199 207
104. R.J. Pettis, I. Hall, D. Costa, and A.J. Hickey Aerosol delivery of muramyl dipeptide to rodent lungs AAPS PharmSci 2 2000 E25
105. P. Muthuswamy, T.C. Hu, B. Carasso, M. Antonio, and N. Dandamudi Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature Chest 107 1995 1621 1630
106. W.W. Yew, J. Lee, and C.H. Chau Role of inhaled budesonide in the treatment of tuberculous pyrexia Chest 118 2000 567
107. E. Sherry, M. Reynolds, S. Sivananthan, S. Mainawalala, and P.H. Warnke Inhalational phytochemicals as possible treatment for pulmonary tuberculosis: two case reports Am J Infect Control 32 2004 369 370
108. O.V. Lovacheva, V.V. Erokhin, N.V. Chernichenko, G.V. Evgushchenko, L.N. Lepekha, and O.A. Rozenberg [Results of use of surfactant in complex therapy of patients with destructive pulmonary tuberculosis] Probl Tuberk Bolezn Legk 2006 12 17
109. G. Chimote, and R. Banerjee Lung surfactant dysfunction in tuberculosis: effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity Colloids Surf B Biointerfaces 45 2005 215 223
110. A.G. Rosas-Taraco, D.M. Higgins, J. Sanchez-Campillo, E.J. Lee, I.M. Orme, and M. Gonzalez-Juarrero Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis Am J Respir Cell Mol Biol 41 2009 136 145
111. A.J. Hickey Pharmaceutical inhalation aerosol technology 2004 Marcel Dekker New York
112. R. Siekmeier, and G. Scheuch Systemic treatment by inhalation of macromolecules-principles, problems, and examples J Physiol Pharmacol 59 Suppl. 6 2008 53 79
113. W.H. Finlay, and A.R. Martin Recent advances in predictive understanding of respiratory tract deposition J Aerosol Med 2008
114. P.M. Smith-Jones, W. Linkesch, and I. Virgolini Interferon-gamma for respiratory diseases Lancet 350 1997 524
115. R.N. Upton, and D.J. Doolette Kinetic aspects of drug disposition in the lungs Clin Exp Pharmacol Physiol 26 1999 381 391
116. M.M. Che, M. Conti, M. Boylan, A.M. Sciuto, R.K. Gordon, and M.P. Nambiar Blood and bronchoalveolar lavage fluid acetylcholinesterase levels following microinstillation inhalation exposure to sarin in Guinea pigs Inhal Toxicol 20 2008 821 828
117. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis (Edinb) 85 2005 227 234
118. J.W. Mouton, U. Theuretzbacher, W.A. Craig, P.M. Tulkens, H. Derendorf, and O. Cars Tissue concentrations: do we ever learn? J Antimicrob Chemother 61 2008 235 237
119. M.J. Derelanko, M.A. Hollinger, Handbook of toxicology 2002 CRC Press Boca Raton
120. S. Suarez, and A.J. Hickey Pharmacokinetic and pharmacodynamic aspects of inhaled therapeutic agents T.B. Martonen, Medical applications of computer modelling: the respiratory system 2002 WIT Press Southampton, UK
121. D.N. McMurray, F.M. Collins, A.M. Dannenberg Jr., and D.W. Smith Pathogenesis of experimental tuberculosis in animal models Curr Top Microbiol Immunol 215 1996 157 179
122. S.A. Cryan, N. Sivadas, and L. Garcia-Contreras In vivo animal models for drug delivery across the lung mucosal barrier Adv Drug Deliv Rev 59 2007 1133 1151
123. H. Sen, S. Jayanthi, R. Sinha, R. Sharma, and P. Muttil Microsphere of two anti-tubercular drugs and a biodegradable polymer administered by inhalation alone or combined with oral route, and process thereof PCT Int Pat Appl 2005 WO/2005/039529
124. J.C. Sung, L. Garcia-Contreras, J.L. Verberkmoes, C.A. Peloquin, K.J. Elbert, and A.J. Hickey Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation Antimicrob Agents Chemother 53 2009 1338 1343
125. L. Garcia-Contreras, J.C. Sung, P. Muttil, D. Padilla, M. Telko, and J.L. Verberkmoes Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs Antimicrob Agents Chemother 54 2010 1436 1442
126. C. Wang, and A.J. Hickey Isoxyl particles for pulmonary delivery: in vitro cytotoxicity and potency Int J Pharm 2010
127. C. Wang, and A.J. Hickey Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles AAPS PharmSci Tech 11 2010 538 549